Evidence map›Paper›PMID 32858399›Full record

ArticleEBioMedicine2020

Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The magnum study.

Tanya Poppe, Benjamin Thompson, James P Boardman, Mark E Bastin, Jane Alsweiler, Gerard Deib, Jane E Harding, Caroline A Crowther, MagNUM Study Group

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Tanya PoppeDepartment of Optometry and Vision Science, University of Auckland, Auckland, New Zealand; Centre for the Developing Brain, Department of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Benjamin ThompsonDepartment of Optometry and Vision Science, University of Auckland, Auckland, New Zealand; School of Optometry and Vision Science, University of Waterloo, Waterloo, Canada.
James P BoardmanCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom; MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom.
Mark E BastinCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Jane AlsweilerDepartment of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.
Gerard DeibDepartment of Radiology, West Virginia University Hospital, W.Va, United States.
Jane E HardingLiggins Institute, University of Auckland, Building 503, Level 2, 85 Park Road, Auckland 1142, New Zealand.
Caroline A CrowtherLiggins Institute, University of Auckland, Building 503, Level 2, 85 Park Road, Auckland 1142, New Zealand. Electronic address: c.crowther@auckland.ac.nz.
MagNUM Study Group
University of Auckland · NZMRC Centre for Reproductive Health · GBUniversity of Edinburgh · GBUniversity of Waterloo · CAWest Virginia University Hospitals · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMagnesium sulphate given to women immediately prior to very preterm birth protects the perinatal brain, so fewer babies die or develop cerebral palsy. How magnesium sulphate exerts these beneficial effects remains uncertain. The aim of the MagNUM Study was to assess the effect of exposure to antenatal magnesium sulphate on MRI measures of brain white matter microstructure at term equivalent age.

methodsNested cohort study within the randomised Magnesium sulphate at 30 to <34 weeks' Gestational age Neuroprotection Trial (MAGENTA). Mothers at risk of preterm birth at 30 to <34 weeks' gestation were randomised to receive either 4 g of magnesium sulphate heptahydrate [8 mmol magnesium ions], or saline placebo, infused over 30 min when preterm birth was planned or expected within 24 h. Participating babies underwent diffusion tensor MRI at term equivalent age. The main outcomes were fractional anisotropy across the white matter tract skeleton compared using Tract-based Spatial Statistics (TBSS), with adjustment for postmenstrual age at birth and at MRI, and MRI site. Researchers and families were blind to treatment group allocation during data collection and analyses.

findingsOf the 109 participating babies the demographics of the 60 babies exposed to magnesium sulphate were similar to the 49 babies exposed to placebo. In babies whose mothers were allocated to magnesium sulphate, fractional anisotropy was higher within the corticospinal tracts and corona radiata, the superior and inferior longitudinal fasciculi, and the inferior fronto-occipital fasciculi compared to babies whose mothers were allocated placebo (P < 0.05).

interpretationIn babies born preterm, antenatal magnesium sulphate exposure promotes development of white matter microstructure in pathways affecting both motor and cognitive function. This may be one mechanism for the neuroprotective effect of magnesium sulphate treatment prior to preterm birth.

fundingHealth Research Council of New Zealand.

Indexed as

BiomarkersMagnetic Resonance ImagingAdultFemaleGestational AgeHumansInfant, NewbornMagnesium SulfateMalePregnancyPrenatal DiagnosisWhite MatterBiomarkersMagnesium Sulfate

Identifiers

PMID32858399
PMCPMC7452670
OpenAlexW3081019401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.